Boehringer Ingelheim joins hands with Meixin health and Yuanxin technology to create an ecosystem for the management of the whole course of patients

Yiouda health on September 26, at the 2021 Xipu meeting, Boehringer Ingelheim signed strategic cooperation agreements with magnesium letter health and Yuanxin technology respectively to explore the innovative health service mode of "medicine medicine insurance" linkage, solve the actual medication problems of patients, and continue to build an ecosystem for the management of the whole course of patients. According to the agreement, Boehringer Ingelheim and magnesium Health launched an innovative payment project, which will make it easier for patients with atrial fibrillation to obtain oral anticoagulants in pharmacies and improve the accessibility of drugs; The innovative form of payment reduces the drug purchase expenditure of patients, alleviates the drug burden, and also helps to improve patients' compliance. The cooperation with Yuanxin technology focuses on the whole course management of patients after leaving the hospital, relying on the new model of Yuanxin pharmacy, hospital side and DTP professional pharmacy to provide the whole process of drug treatment management and health services for the public. In the future, the two sides will further explore cooperation in medical treatment management and health services such as doctor-patient education, covering solutions such as digital driven marketing and innovative payment for pharmaceutical enterprises; One stop service solutions for doctors such as academic exchange, education and training, multi-point practice and patient management; And patient oriented disease science popularization, medication guidelines, standardized medication services and many other contents. "The cooperation with mgxin health and Yuanxin technology marks another important step for Boehringer Ingelheim in the management of the whole course of patients, which will improve the management level of related diseases and reduce the economic burden of medication for related patients." said Dr. Dong Bowen, general manager of human drugs in Greater China of Boehringer Ingelheim.